TAG:
pathologist compensation
AP Groups Can Protect Revenue, Pathologist Compensation
CEO SUMMARY: Many anatomic pathology groups are watching their revenue decline and margins shrink on the same or greater case volume. These trends make it imperative to have a deeper understanding of the operational and financial variables that contribute to stability in the group’s fi…
Is There A Power Shift in Pathology?
SINCE THE END OF WORLD WAR II, the dominant practice model for the pathology profession has been the private group practice. Outside of academia and a few other settings, the vast majority of pathologists practiced laboratory medicine as physician-partners in a medical group. During this same period…
Doctors’ Income Survey Includes Pathologists
CEO SUMMARY: Information on the year-to-year change in average total cash compensation for physicians shows that income is not keeping pace with inflation. That is not news to the physician community. However, pathologists continue to earn compensation that is above the midpoint average f…
Aligning Pathologist Productivity With Compensation Can Be Challenging
“Growing interest in ways to link a pathologist’s productivity to his/her compensation makes this a widely-discussed topic within many pathology group practices.” –Dennis Padget CEO SUMMARY: Part Three continues THE DARK REPORT’S series on meas…
Measuring Daily Productivity of Pathologists Can Be Complex
“Conflict in groups stems from trying to use one measurement system to meet all practice goals. This is the pitfall to avoid.” —Dennis Padget CEO SUMMARY: Productivity measurement systems are widely used outside the healthcare industry to bet…
AmeriPath Reports on 2003, Its First Year as a Private Firm
WILL BUSINESS BE BETTER for AmeriPath, Inc. as a private company than it was as a publicly-traded firm? Its 2003 financial report indicates some interesting challenges, many common to all laboratories. First, a look at basic numbers. AmeriPath’s net revenues grew from $478.8 milli…
Pathology Group Conflicts Over Equity Vs. Salary
CEO SUMMARY: During the next two years, two of every three pathology group practices will see a change in pathologists, either through new hires or by resignation and retirement. These events fundamentally change the financial situation of the group, but since most groups are organized un…
AmeriPath Will Acquire Inform DX for $44.6 Mil
CEO SUMMARY: It’s another example of consolidation in the anatomic pathology marketplace. AmeriPath, Inc.’s acquisition of Inform DX, Inc. positions the company to do as much as $350 million in revenues next year. By acquiring Inform DX, AmeriPath also gains entry into six more states…
Selling A Path Practice Requires Knowledge, Savvy & Good Timing
CEO SUMMARY: Historically, there was virtually no market for buying and selling pathology practices. That is rapidly changing as the first pathology practice management (PPM) companies enter the marketplace. Their business plan requires them to acquire pathology practices if they are to g…
CURRENT ISSUE
Volume XXVII No. 9 – June 22, 2020
THE NEWS ON THE SEROLOGICAL TEST FRONT is discouraging, even bleak, as THE DARK REPORT analyzes the outcome of the FDA’s own review of 11 tests previously listed as marketable. Only three tests passed the review, and yet a quality control expert consulted by THE DARK REPORT has dim views of the FDA’s testing operation, leading to even more doubts. Also, health insurers are scraping away at mandated COVID-19 test reimbursements, leaving lab revenues once again at their mercy.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Need A Group Membership? Company Discounts are Available!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
